PBHE315

Introduction

Prescription medications account for virtually 10 percent of the total health expenditure in the United States, adding up $263 billion every year.
National and States governments have concentrated on magnificently managing these expenses through a range of approaches.

Thesis statement

The presence of government-protected control rights for drug companies is the leading factor that pushes prescription drug costs higher in the US than any other country in the world. The reason behind these high prices are;

Pharmaceutical companies in the US, unlike any other country in the world, set their prices on the drugs.

In 2003, the Republican majority House formed the Medicare drug benefit which stripped the program that protects over 40 million Americans from discussing drug charges. Medicaid, in response, must inclusively cover every other approved drug by the Food and Drug Administration, even if there are a cheaper more efficient drug is on the market.

Allowing certain drug from drug companies to the market hence averting generics from the market to reduce costs.

In a determination to encourage innovation, the U.S. has a patent scheme that permits drug industrialists to continue being the only producers. The FDA similarly provides pharmaceutical companies exceptionality for certain products, comprising those that treat persons with different illnesses.

Application accumulations at the FDA lead to delays to the generic companies before they can get authorization to produce drugs that are not unproven.

Some federal rules prevent the generics companies’ abilities to lower the prices of the drugs.

In the U.S, is an obligatory by law for Pharmacists in more than 25 states to get a patient permission before swapping to a generic drug.
In 2006, Medicaid incurred a loss of approximately 19 million dollars for one drug just because pharmacists couldn’t get patient accord and Medicaid ought to pay for the higher that drug even nevertheless a low-cost product was obtainable.

Conclusion

Dealing with America’s drug charges complications is not and will not be a simple task. Congressional holdup and the supremacy of the pharmaceutical foyer make permitting Medicare to discuss Part D costs an improbable option.
The legislators also have a big role to play in this task, and they must come up with a way to make tighter guidelines and reinforce the inaccuracy adjoining patent fortifications in an exclusive way devoid of alarming innovation.
It is until then the ordinary American citizen will suffer from the high drug prices from this pharmaceutical companies.